Sarepta Therapeutics, Inc. Share Price Today: Live Updates & Key Insights

Sarepta Therapeutics, Inc. share price today is $16.6, up 0.24%. The stock opened at $16.85 against the previous close of $16.65, with an intraday high of $17.29 and low of $16.54.

Sarepta Therapeutics, Inc. Share Price Chart

Sarepta Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Sarepta Therapeutics, Inc. Share Price Performance

$16.6 0.0024(0.24%) SRPT at 23 Mar 2026 03:20 PM Biotechnology
Lowest Today 16.54
Highest Today 17.29
Today’s Open 16.85
Prev. Close 16.65
52 Week High 76.67
52 Week Low 10.42
Day’s Range: Low 16.54 High 17.29
52-Week Range: Low 10.42 High 76.67
1 day return -
1 Week return +0.24
1 month return -7.84
3 month return -21.36
6 month return -10.53
1 year return -78.11
3 year return -87.07
5 year return -79.99
10 year return -

Sarepta Therapeutics, Inc. Institutional Holdings

BlackRock Inc 12.57

Vanguard Group Inc 11.25

AQR Capital Management LLC 7.43

iShares Core S&P Small-Cap ETF 6.06

State Street Corp 5.05

First Trust NYSE Arca Biotech ETF 3.25

State Street® SPDR® S&P® Biotech ETF 3.12

Vanguard Total Stock Mkt Idx Inv 3.03

Erste Asset Management GmbH 2.60

Two Sigma Investments LLC 2.33

Vanguard Small Cap Index 2.15

Aberdeen Group PLC 2.14

Two Sigma Advisers, LLC 1.97

First Trust Advisors L.P. 1.90

UBS Group AG 1.90

Morgan Stanley - Brokerage Accounts 1.86

Geode Capital Management, LLC 1.81

D. E. Shaw & Co LP 1.47

T. Rowe Price Investment Management,Inc. 1.30

JPMorgan Chase & Co 1.28

Federated Hermes Inc 1.25

Vanguard Small Cap Growth Index Inv 1.19

Renaissance Technologies Corp 1.10

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Connor Clark & Lunn Inv Mgmt Ltd 1.03

Citigroup Inc 0.97

Millennium Management LLC 0.95

State Street SPDR Port S&P 600 Sm CpETF 0.93

abrdn Healthcare Opportunities 0.92

abrdn Healthcare Investors 0.90

Federated Hermes MDT MCG Institutional 0.77

Federated Hermes MDT Mid Cap Growth A 0.77

First Trust Health Care AlphaDEX® ETF 0.72

iShares Biotechnology ETF 0.70

Vanguard Tax-Managed Small Cap Adm 0.67

State St Russell Sm/Mid Cp® Indx SL Cl I 0.52

iShares S&P Small-Cap 600 Growth ETF 0.52

Fidelity Extended Market Index 0.52

iShares Russell Mid-Cap Growth ETF 0.50

Schwab US Small-Cap ETF™ 0.49

Sarepta Therapeutics, Inc. Market Status

Strong Buy: 14

Buy: 8

Hold: 4

Sell: 0

Strong Sell: 0

Sarepta Therapeutics, Inc. Fundamentals

Market Cap 1752.28 M

PB Ratio 1.5372

PE Ratio 0.0

Enterprise Value 1853.42 M

Total Assets 3349.70 M

Volume 2864089

Sarepta Therapeutics, Inc. Company Financials

Annual Revenue FY25:2198237000 2198.2M, FY24:1901979000 1902.0M, FY23:1104982000 1105.0M, FY22:933013000 933.0M, FY21:701887000 701.9M

Annual Profit FY25:-1054985000 -1055.0M, FY24:1901979000 1902.0M, FY23:968016000 968.0M, FY22:793024000 793.0M, FY21:604838000 604.8M

Annual Net worth FY25:-842789000 -842.8M, FY24:235239000 235.2M, FY23:-690876000 -690.9M, FY22:-703488000 -703.5M, FY21:-418780000 -418.8M

Quarterly Revenue Q4/2025:442934000 442.9M, Q3/2025:399356000 399.4M, Q2/2025:611091000 611.1M, Q1/2025:744856000 744.9M, Q4/2024:658412000 658.4M

Quarterly Profit Q4/2025:-2369391000 -2369.4M, Q3/2025:248581000 248.6M, Q2/2025:458533000 458.5M, Q1/2025:607292000 607.3M, Q4/2024:658412000 658.4M

Quarterly Net worth Q4/2025:-412226000 -412.2M, Q3/2025:-179947000 -179.9M, Q2/2025:196892000 196.9M, Q1/2025:-447508000 -447.5M, Q4/2024:159049000 159.0M

About Sarepta Therapeutics, Inc. & investment objective

Company Information Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 835

Industry Biotechnology

CEO Mr. Douglas S. Ingram Esq., J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Sarepta Therapeutics, Inc. FAQs

What is the share price of Sarepta Therapeutics, Inc. today?

The current share price of Sarepta Therapeutics, Inc. is $16.6.

Can I buy Sarepta Therapeutics, Inc. shares in India?

Yes, Indian investors can buy Sarepta Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Sarepta Therapeutics, Inc. shares in India?

You can easily invest in Sarepta Therapeutics, Inc. shares from India by:

Can I buy fractional shares of Sarepta Therapeutics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. has a market cap of $1752.28 M.

In which sector does Sarepta Therapeutics, Inc. belong?

Sarepta Therapeutics, Inc. operates in the Biotechnology sector.

What documents are required to invest in Sarepta Therapeutics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Sarepta Therapeutics, Inc.?

The PE ratio of Sarepta Therapeutics, Inc. is N/A and the PB ratio is 1.54.